Vertex Pharmaceuticals (VRTX) Change in Cash (2009 - 2026)

Vertex Pharmaceuticals' Change in Cash history runs 18 years deep, the most recent figure standing at $417.1 million for Q1 2026.

• On a quarterly basis, Change in Cash rose 268.46% year-over-year to $417.1 million in Q1 2026; TTM through Mar 2026 was $819.5 million, a 118.28% increase from a year earlier, with the FY2025 full-year figure at $515.6 million, up 108.89% from the prior year.
• Change in Cash rose to $417.1 million in Q1 2026 per VRTX's latest filing, from $140.0 million in the prior quarter.
• Across five years, Change in Cash topped out at $1.3 billion in Q4 2022 and bottomed at -$4.6 billion in Q2 2024.
• The 5-year median for Change in Cash is $296.6 million (2025), against an average of -$76.2 million.
• Across the five-year window, Change in Cash jumped 554.96% in 2022 and sank 633.74% in 2024, its largest moves.
• Year by year, Change in Cash stood at $1.3 billion in 2022, then plunged by 155.75% to -$744.3 million in 2023, then advanced by 9.19% to -$675.9 million in 2024, then surged by 120.71% to $140.0 million in 2025, then soared by 197.93% to $417.1 million in 2026.
• Per Business Quant, the three latest VRTX Change in Cash figures stand at $417.1 million (Q1 2026), $140.0 million (Q4 2025), and -$34.2 million (Q3 2025).